BCR and B-cell chronic lymphocytic leukemia: Despite the overall lower BCR signaling caused by CLL exposure to ibrutinib, ibrutinib-treated CLL cells unexpectedly retained their capability to activate VLA-4 upon anti-IgM triggering.